Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 10/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238915 | 0.99 | DPP4 (0.52) | DPP4HSD17B10ALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL5234491 | 0.92 | DPP4 (0.47) | DPP4ADORA2AADORA2BADORA1PSEN1 | |
| Hydrochloric Acid SCHEMBL5236314 | 0.91 | DPP4 (0.44) | DPP4ALDH1A1PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL5235033 | 0.91 | DPP4 (0.44) | DPP4KDM4EMAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5234616 | 0.89 | DPP4 (0.43) | DPP4HSD17B10ALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL5239297 | 0.89 | DPP4 (0.43) | DPP4HSD17B10ALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL5239042 | 0.87 | DPP4 (0.69) | DPP4 | |
| Hydrochloric Acid SCHEMBL5234677 | 0.87 | DPP4 (0.46) | DPP4HSD17B10ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL5238860 | 0.87 | DPP4 (0.42) | DPP4ALDH1A1KDM4EMAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL5233326 | 0.86 | DPP4 (0.41) | DPP4KDM4ELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3023095-B2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2023-11-08 | — | — | EP | disclosed |
| EP-3738585-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3366283-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-3023095-B1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| EP-3023095-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-2839832-A2 | Use of dipeptidyl peptidase IV inhibitors | Novartis AG (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-20140287040-A1 | Formulation | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140205663-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20130052239-A1 | Formulation | JOSHI YATINDRA (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | KOWALSKI JAMES (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2006047248-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METFORMIN | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| WO-2006041976-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006005613-A1 | COMBINATION OF DPP-IV INHIBITORS AND COMPOUNDS MODULATING 5-HT3 AND/OR 5-HT4 RECEPTORS | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005117861-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005079795-A2 | DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS | NOVARTIS AG (CH) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005067976-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005049022-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049088-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTIOBESITY OR APPETITE REGULATING AGENT | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885HSD17B10 640/4885ALDH1A1 387/4885 |
| US-20140205663-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885HSD17B10 2641/4885ALDH1A1 2221/4885 |
| US-20140287040-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885HSD17B10 1507/4885ALDH1A1 737/4885 |
| US-20130052239-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885HSD17B10 1507/4885ALDH1A1 737/4885 |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885HSD17B10 2641/4885ALDH1A1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.